JJ. Low molecular weight fibroblast growth factor-2 signals via protein kinase C and myofibrillar proteins to protect against postischemic cardiac dysfunction. Am J Physiol Heart Circ Physiol 304: H1382-H1396, 2013. First published March 11, 2013 doi:10.1152/ajpheart.00613.2012.-Among its many biological roles, fibroblast growth factor-2 (FGF2) acutely protects the heart from dysfunction associated with ischemia/reperfusion (I/R) injury. Our laboratory has demonstrated that this is due to the activity of the low molecular weight (LMW) isoform of FGF2 and that FGF2-mediated cardioprotection relies on the activity of protein kinase C (PKC); however, which PKC isoforms are responsible for LMW FGF2-mediated cardioprotection, and their downstream targets, remain to be elucidated. To identify the PKC pathway(s) that contributes to postischemic cardiac recovery by LMW FGF2, mouse hearts expressing only LMW FGF2 (HMWKO) were bred to mouse hearts not expressing PKC␣ (PKC␣KO) or subjected to a selective PKCε inhibitor (εV1-2) before and during I/R. Hearts only expressing LMW FGF2 showed significantly improved postischemic recovery of cardiac function following I/R (P Ͻ 0.05), which was significantly abrogated in the absence of PKC␣ (P Ͻ 0.05) or presence of PKCε inhibition (P Ͻ 0.05). Hearts only expressing LMW FGF2 demonstrated differences in actomyosin ATPase activity as well as increases in the phosphorylation of troponin I and T during I/R compared with wild-type hearts; several of these effects were dependent on PKC␣ activity. This evidence indicates that both PKC␣ and PKCε play a role in LMW FGF2-mediated protection from cardiac dysfunction and that PKC␣ signaling to the contractile apparatus is a key step in the mechanism of LMW FGF2-mediated protection against myocardial dysfunction. low molecular weight FGF2; PKC␣ and ε; troponin; actomyosin ATPase; postischemic cardiac function CARDIOVASCULAR DISEASE IS the number one killer in the U.S., and every year over eight million people in the U.S. suffer from myocardial infarction (43). Often, myocardial ischemia is characterized by lowered postischemic left ventricular function, which is associated with increased morbidity and mortality (7). There is a profound and immediate need to address the problem of myocardial dysfunction and infarction associated with cardiac ischemia and reperfusion (I/R). One promising therapeutic strategy to alleviate I/R-induced cardiac injury is fibroblast growth factor-2 (FGF2).
the treatment of cardiac patients; however, while in recent years, there have been a number of noteworthy developments characterizing the mechanism of action of FGF2 in the ischemic heart, there are several unanswered questions that must be addressed before FGF2 becomes a therapeutic molecule. Yet to be determined is the distinct role each FGF2 isoform plays in the ischemic heart. FGF2 includes two classes of protein isoforms, the low molecular weight (LMW) and the high molecular weight (HMW; Refs. 18, 20) . LMW FGF2 is ϳ18 kDa in both mouse and human and is found primarily in the cytosol of the cell and extracellular fluid as well as nucleus (20, 39, 40) . HMW FGF2 differs from LMW in that it includes a nuclear localization signal and encompasses two isoforms in mouse (21) (22) and four in humans (21-34 kDa) (20, 40) . Our laboratory, using gain-of-function and loss-of-function genetic mouse models, has demonstrated that all endogenous FGF2 isoforms are necessary for protection against myocardial infarction (40, 41) , whereas HMW and LMW FGF2 isoforms play opposing roles in the recovery of the heart from I/R injury (40, 41) . Studies using genetically modified mice with only LMW FGF2 expression (HMWKO), or wild-type mouse hearts with LMW FGF2 exogenously added, have shown that this isoform is protective against postischemic dysfunction (30, 40, 41) , while hearts with only the HMW isoforms (LMWKO), or with HMW FGF2 overexpressed, have significantly lower postischemic cardiac function (40) . However, the pathways involved in signal transduction for each isoform subtype during I/R-induced cardiac dysfunction have not yet been elucidated; this information is critical for understanding the actions of FGF2 in the postischemic heart.
Our laboratory has previously identified protein kinase C (PKC) as necessary for mediating the protection against cardiac dysfunction seen in mouse hearts overexpressing all LMW and HMW isoforms of FGF2 (27) , which suggests that PKC is critical to the signaling mechanisms of LMW and HMW FGF2 effects on the heart during I/R. Among the isoforms that are activated by overexpression of FGF2 in the mouse heart that may also phosphorylate targets modulating cardiac function are PKCε and ␣ (1, 5, 9, 17, 22, 27, 33, 34, 46, 53) . PKCε has been shown to localize to the cross-striated structures when activated (17, 27, 52) and is known to phosphorylate troponin I (TnI) and troponin T (TnT), as well as myosin light chain and myosin binding protein C (MyBP-C), which modulates calcium sensitivity of the myofilaments in the heart (34) . Similarly, PKC␣ is known to translocate to myofibrillar structures (67) and can modulate the function of TnT, TnI, and MyBP-C (34). Finally, PKCε and PKC␣ have been shown to be necessary for ischemic preconditioning (23, 70) , and PKC␣ has been shown to be activated in the heart associated with sevofluorane-and sildenafil-induced cardioprotection (16, 32) . However, these kinase cascades are complex and stimulus dependent (21, 29) , which is why it is essential to delineate the isoforms of PKC, as well as their downstream targets, that mediate LMW FGF2's protective actions.
Based on our previous findings that demonstrated that the individual FGF2 isoforms have opposing action on postisch- There is no significant difference in FGFR1 expression in all groups similar to that previously published by our laboratory (40) ; n ϭ 6 -11 hearts per genotype. Heart snap frozen for PKC activation and myofibril protein level and activity emic cardiac function but not on infarct size (40, 41) , the current study focuses on the cardiac function effects modulated by LMW FGF2 during acute I/R injury. Here, our laboratory seeks to elucidate, for the first time, a mechanism by which endogenously expressed LMW FGF2 protects the heart, identifying the isoforms of PKC that are directly responsible and determining their role in modulating myofibrillar protein function. Our study reveals that PKC␣ and -ε are selectively activated and translocate to the myofibril at early ischemia or reperfusion, respectively, and that ablation of PKC␣ and inhibition of PKCε abrogate the protective effects of LMW FGF2 against postischemic cardiac dysfunction. These data also demonstrate that expression of only LMW FGF2 results in differential phosphorylation of troponin I and T and alteration of actomyosin MgATPase activity during I/R, which is dependent on PKC and suggest that the improvement in postischemic contractile function mediated by LMW FGF2 is due to direct targeting of the PKC␣ and ε to the myofibril.
METHODS

Mouse Models
Generation and characterization of HMW FGF2 knockout (HMWKO) mice, which only express LMW FGF2, on a SV 129/Black Swiss mixed background, have been previously described (3, 40) . To test the role of PKC␣, HMWKO mice were bred to mice lacking expression of PKC␣ (PKC␣KO) on a mixed background (SV 129/Black Swiss/ FVBN), which has been previously described (9) . Mice that did not express either the HMW isoforms of FGF2 or PKC␣ (HMWKOx-PKC␣KO) were found to have no changes in the expression of other PKC isoforms or LMW FGF2 compared with HMWKO hearts (Fig. 1) . Similarly, there were no differences in fibroblast growth factor receptor (FGFR1) expression, the predominant FGFR in mouse heart, in these genotypes ( Fig. 1 ) and as previously demonstrated by our laboratory (40) . All mice were randomly assigned to studies and compared with their wild-type littermates (n ϭ 3-16 per study/ genotype). All animal protocols were submitted to and approved by the University of Cincinnati Institutional Animal Care and Use Committee. Mice were housed in pathogen-free housing according to standard use protocols, animal welfare regulations, and the National Institutes of Health Guide for the Care and Use of Laboratory Animals (Bethesda, MD).
Exclusion Criteria
In the I/R studies, aortic leak (pressure Ͻ60 mmHg on retrograde perfusion), pulmonary vein leak (aortic flow of Ͻ2.0 ml/min and a perfusate gas PO 2 Ͼ380 mmHg, with low atrial pressure Ͻ 4 mmHg), or a visible leak in the heart itself (i.e., hole in ventricle or atrium) was the basis for exclusion, and a total of 17 mice were excluded. Aortic leak was represented as an aortic pressure Ͻ60 mmHg on Langendorff, retrograde perfusion mode. Pulmonary vein leak was demonstrated as an aortic flow Ͻ2.0 ml/min, low (Ͻ4 mmHg) atrial pressure, and a perfusate gas PO 2 Ͼ380 mmHg or a visible leak (i.e., hole in ventricle or atrium) in the heart.
I/R Injury
Ten-to twelve-week-old, sex-matched mice were anesthetized with pentobarbital sodium (80 mg/kg ip), and anesthesia was confirmed by a lack of response to painful stimulus (toe pinch). Hearts were rapidly excised, the aorta and pulmonary vein were rapidly cannulated to induce a working-heart system with a cardiac output of 5 ml/min and a constant afterload of 50 mmHg, and establishment of baseline cardiac and hemodynamic parameters of cardiac output, aortic pressure, aortic and coronary flow, left ventricular systolic and diastolic pressure, and contractility (ϩdP/dt, positive derivative of the left ventricular pressure with respect to time), and relaxation (ϪdP/dt, negative derivative of the left ventricular pressure with respect to time) occurred. Mouse hearts were subjected to global low-flow I/R injury as previously described (26) . Ischemia was induced by reducing total cardiac output from 5 to 1 ml/min for 1 h resulting in a Ͼ90% reduction in coronary flow, after which the heart was reperfused at 5 ml/min for 2 h. icity colorimetric assay per the manufacturers' instructions and normalized to heart weight and coronary flow.
Pharmacological Agents
To examine the role of PKCε, TAT-conjugated translocation inhibitor εV1-2 and the TAT peptide (vehicle) were dissolved in water and administered to the heart via circulation of the Kreb's perfusate buffer 15 min before ischemia to 15 min after the onset of ischemia, as well as 15 min before reperfusion to 15 min after the onset of reperfusion (Fig. 2) . A concentration response curve (10 nM-1 M) was performed to identify the maximal efficacy of inhibitor without adverse effects. A concentration of 100 nM was found to effectively block the translocation of PKCε, while not affecting the activation of PKC isoforms ␣, ␦, and (data not shown).
Cardiac Preparation and Immunoblotting for Detection of FGF2
Snap-frozen nonischemic hearts were powdered and homogenized in homogenization buffer (20 mM Tris, 2 mM EDTA, 2 M NaCl, 1% NP40, and PMSF), and FGF2 was extracted as previously described (26) . Western blot analysis of the extracted FGF2 was performed with a rabbit polyclonal antibody to FGF2 (1:1,000; Santa Cruz Biotechnology). Levels of FGF2 protein isoforms were visualized by chemiluminescence (Amersham Bioscience). Densitometry of protein bands was performed using a Fluorchem 8800 gel imager (Alpha Innotech).
Whole Heart Preparation to Detect FGFR Activation
Snap-frozen nonischemic hearts (wild type) were powdered and homogenized in homogenization buffer (25 mM HEPES, pH 7.5, 1% glycerol, 150 mM NaCl, 1% Triton X-100, 5 mM EDTA, 1 mM sodium orthovandate, 25 mM ␤-glycerolphosphate, 50 mM sodium fluoride solid, 0.5 M okadaic acid, diisopropylfluorophosphate, 100 M calpain inhibitor, Pefabloc stock 1 and 2, and Sigma phosphatase inhibitor) as previously described (30, 40, 41) . The homogenate was centrifuged at 13,000 g for 15 min, and the supernatant was collected. Protein concentration was determined via Bio-Rad Lowry protein assay (Bio-Rad, Hercules, CA).
Western Immunoblotting for FGFR1 Expression
One hundred micrograms of whole cell homogenate were loaded onto an 8% SDS-PAGE gel and then transferred onto 0.2 m nitrocellulose membrane. Transfer efficiency and loading equality were examined by staining the membrane with 0.1% Ponceau S in 5% acetic acid. The membrane was blocked in 5% dry milk and then incubated with primary antibody against total FGFR1 (1:500; Cell Signaling) followed by incubation with horseradish peroxidase-conjugated secondary mouse (1:10,000; Bio-Rad) antibody. FGFR1 expression was visualized by ECL, and densitometry of protein bands was quantitated using a Fluorchem 8800 gel imager and normalized to calsequestrin [primary antibody dilution 1:2,500 (Thermo Scientific), and horseradish peroxidase-conjugated secondary goat anti-rabbit antibody dilution 1:5,000 (Santa Cruz Biotechnology)].
PKC Phosphorylation and Translocation to the Myofibril
Activation of PKC isoforms by phosphorylation or translocation to the myofibril was measured as previously described (68) . Hearts were snap frozen at key time points during I/R (see Fig. 2 ). PKC activation in the whole heart samples or myofilaments was analyzed with immunoblotting, as described below. The time points were chosen to reflect times when PKC␣, ␦, and ε have been shown by our laboratory to be activated during I/R (26) .
PKC phosphorylation via immunoblotting (whole heart). Hearts were homogenized in a Tris buffer containing a nonionic detergent (Tween-20) with protease and phosphatase inhibitors and analyzed with SDS-PAGE electrophoresis using 12% separating gels. Nitrocellulose membranes were probed for antibodies for phosphorylated PKCε, ␣, and ␦ (1:500; Santa Cruz) and then stripped and reprobed with antibodies against the total form of the kinase (1:500; Santa Cruz). Activation is indicated as a ratio of phosphorylated kinase to total kinase.
PKC translocation via immunoblotting (myofilament).
Myofilament proteins (75 g) were resolved by SDS-PAGE electrophoresis using 10% separating gels. Proteins were transferred to nitrocellulose membranes and probed with antibodies for PKC␣, PKC␦, and PKCε (BD Biosciences, Mississauga, ON, Canada; and Upstate, Mississauga, ON, Canada). Protein loading was assessed by probing with an anti-actin antibody (Millipore, Etobicoke, ON, Canada). Secondary antibodies were conjugated to horseradish peroxidase. Primary antibodies were used at 1:1,000 dilution, except for anti-actin, which was 1:25,000. Secondary antibodies were used at 1:5,000 dilution. PKC bands were detected using Western Lightning (PerkinElmer Life and Analytical Sciences, Woodbridge, ON, Canada), and analysis of band density was done using ImageJ software. All bands were normalized to their respective controls and are expressed as a percent change in band density. As the PKC immunoblots were conducted using myofilament isolations, sarcomeric ␤-actin was used as a loading control.
Myofilament Isolation
Cardiac myofilaments were prepared as previously described (33) . Hearts collected at specific time points of I/R (see Fig. 2 ) were homogenized in ice-cold standard buffer [60 mM KCl, 2 mM MgCl 2, 30 mM imidazole (pH 7.0), 0.2 mM PMSF, 0.1 mM leupeptin, and 0.01 mM pepstatin A]. After centrifugation (12,000 g for 15 min at 4°C), the pellets were resuspended in ice-cold skinning buffer [1% Triton X-100, 10 mM EGTA, 8.2 mM MgCl 2, 14.4 mM KCl, 60 mM imidazole (pH 7.0), 5.5 mM ATP, 12 mM creatine phosphate, 10 U/ml creatine phosphokinase, 0.2 mM PMSF, 0.1 mM leupeptin, and 0.01 mM pepstatin A] and gently mixed for 45 min at 4°C. The suspension was centrifuged (1,100 g for 15 min at 4°C), and the pellets were washed three times in cold standard buffer. Protein concentration was measured using a Bradford assay.
Actomyosin MgATPase Analysis
Myofilaments isolated from snap-frozen hearts (see Fig. 2 ) were subjected to an actomyosin MgATPase activity as previously described (68) . Purified myofilaments (50 g) were incubated in activating buffers containing various amounts of free Ca 2ϩ at 32°C for 5 min. Activating buffers were made by mixing maximally activating and relaxing ATPase buffers. Maximally activating ATPase buffer contained 23.5 mM KCl, 5 mM MgCl 2, 3.2 mM ATP, 2 mM EGTA, 20 mM imidazole, 2.2 mM CaCl2, 0.2 mM PMSF, 0.1 mM leupeptin, and 0.01 mM pepstatin A (pH 7.0). The relaxing ATPase buffer contained 26 mM KCl, 5.1 mM MgCl 2, 3.2 mM ATP, 2 mM EGTA, 20 mM imidazole, 4.9 M CaCl2, 0.2 mM PMSF, 0.1 mM leupeptin, and 0.01 mM pepstatin A (pH 7.0). Free Ca 2ϩ was calculated using the program of Patton et al. (48) . Reactions were quenched with equal volumes of 10% trichloroacetic acid. The samples were centrifuged (14,100 g for 3 min), and the supernatant was removed for phosphate analysis. The amount of inorganic phosphate released was determined colorimetrically by adding an equal amount of developing solution (0.5% FeSO 4-0.5% ammonium molybdate in 0.5 M H2SO4) to the supernatant and measuring absorbance at 630 nm.
Myofibrillar Protein Phosphorylation Analysis
Myofilament proteins (40 g) were separated on 12.5% SDS-PAGE gels. Gels were fixed in 50% methanol-10% acetic acid at room temperature overnight, and phosphorylated proteins were stained with Pro-Q Diamond (Molecular Probes, Eugene, OR), according to the manufacturer's instructions. Imaging was done using a Typhoon gel scanner (GE Healthcare, Baie d'Urfé, QC, Canada), and analysis was done using ImageJ software (National Institutes of Health). Protein loading was assessed by Coomassie staining of gels after imaging.
Statistical Analysis
Values are presented as means Ϯ SE of n independent experiments. The number of individuals for each study was determined by power analysis referencing previous studies that made use of each method. One-way ANOVA was performed for the postischemic functional recovery of hearts before and after I/R injury, followed by a post hoc Student's t-test. One-or two-way ANOVA was used to analyze the significance of the results among three or more independent groups within groups of untreated samples (one-way) or the presence or absence of treatments for evaluation of time course data (two-way). Probabilities of 0.05 or less are considered statistically significant. 
RESULTS
Expression of only LMW FGF2 results in differential activation of PKC isoforms during I/R injury. Previous studies from our laboratory have established that PKC is required for cardioprotection induced by overexpression of all isoforms of FGF2 (26), but it is unclear if this is also the case for the improvement in postischemic function seen when only LMW FGF2 is expressed. To evaluate changes in PKC activation at key time points during I/R, the phosphorylation of PKC isoforms was examined in HMWKO and wild-type hearts (Fig. 2) . Hearts expressing only the LMW isoform of FGF2 and wildtype hearts showed similar activation of PKC␣, ␦, and ε at baseline (Fig. 3) . At the onset of ischemia, PKC␣ showed higher activation (ϳ20%) in hearts only expressing LMW FGF2 (HMWKO) compared with wild type; this degree of PKC activation correlates to that seen in other forms of cardioprotection sufficient to significantly reduce I/R injury, both in terms of activation by phosphorylation (62) and translocation (49) . Similarly, HMWKO hearts showed higher activation of PKCε compared with wild type at early reperfusion (P Ͻ 0.05).
Improved postischemic functional recovery of LMW expressing hearts is ablated in the absence of PKC␣ or presence of PKCε inhibition. It was next determined whether these changes in the phosphorylation state of PKC␣ at early ischemia, and PKCε at early reperfusion (Fig. 3) , play a role in LMW FGF2-mediated protection from cardiac dysfunction. As previously seen (40) , HMWKO hearts showed a significantly higher postischemic recovery of cardiac function than wild type (Fig. 4, A and B) . Breeding these mice with genetically modified mice that lack PKC␣ expression (PKC␣KO) resulted in a complete abrogation of this protection (P Ͻ 0.05; Fig. 4A) . No difference in postischemic functional recovery was seen in hearts with PKC␣ ablation, but with HMW FGF2 expression intact (PKC␣KO) compared with wild-type cohorts, suggesting that PKC␣ has little influence on function following I/R injury in our models, without activation by LMW FGF2. Similarly, while a TAT peptide alone had no effect on either wild-type or HMWKO hearts, a TAT-conjugated PKCε inhibitor administered during I/R attenuated the recovery of ϩdP/dt, but not ϪdP/dt, of HMWKO heart (P Ͻ 0.05; Fig. 4B ). Other preischemic and postischemic functional parameters for normal PKC␣ expression and PKC␣ ablated or untreated and PKCε inhibitor-treated wild-type and HMWKO hearts are shown in Tables 1, 2 , 3, and 4, respectively. There were no differences in preischemic functional parameters among all genotypes or treatment groups. Following I/R injury, there was significant systolic and diastolic dysfunction as measured by left ventricular pressure, ϩdP/dt and, ϪdP/dt in mice expressing LMW FGF2 but not PKC␣ (HMWKOxPKCa; P Ͻ 0.05; Table 1 ). Similarly, inhibition of PKCε in mice expressing only LMW FGF2 resulted in postischemic systolic and diastolic dysfunction as represented by ϩdP/dt and ϪdP/dt (P Ͻ 0.05; Table 3 ).
Myocardial cell death was represented as LDH release measured from coronary effluent at designated time points of baseline, ischemia, and reperfusion (Fig. 2) . There was a significant increase in LDH release at early reperfusion compared with baseline values in all groups (P Ͻ 0.05; Tables 2 and 4), suggesting this is an irreversible I/R model as previously described by our laboratory (26) . Yet, there was no difference in LDH release at early reperfusion between the groups. These findings confirm our previously published studies, suggesting that the primary protective effects of this FGF2 isoform lie in the prevention of contractile dysfunction, whereas both the LMW and HMW are involved in infarct reduction (40, 41) .
Cross talk between PKC␣ and ε in HMWKO hearts does not occur during I/R injury. As both PKCε and PKC␣ are neces- sary for the protection of the heart from I/R-mediated functional injury in HMWKO mice, cross talk between the two was evaluated by measuring the activation of PKCε in the absence of PKC␣ and the activation of PKC␣ in the presence of PKCε inhibition. There was no decrease in PKCε activation in the absence of PKC␣, and in fact there was a slight increase, indicating that PKC␣ does not activate PKCε further downstream (Fig. 5A) . Similarly, there was no change in the phosphorylation of PKC␣ in the presence of PKCε inhibition (Fig.  5B) , suggesting that the activation of PKC␣ is not dependent on the epsilon isoform.
Translocation of PKC isoforms to the myofibril is altered in LMW expressing hearts during I/R. As LMW FGF2 expression increases the function of the heart after I/R injury, the relevance of myofibrillar proteins in LMW FGF2-mediated PKC signaling during cardiac ischemia was investigated. Translocation of PKC isoforms to the myofibrils was measured at key time points during I/R. In sham hearts, significant differences in the levels of PKC␦, ε, and ␣ at the myofibrils were seen in the HMWKO compared with wild type (Fig. 6 ), although no difference in the phosphorylation of these isoforms was seen at this time point (Fig. 3) , suggesting that the localization to the myofibril but not phosphorylation of these PKCs is altered. After the onset of ischemia, myofilament PKC␣ levels increased and levels of PKC␦ decreased in HMWKO hearts compared with wild-type cohorts. After reperfusion, levels of PKCε at the myofibril increased. The timing of the translocation of PKC␣ and ε mirrors the phosphorylation of these isoforms (Fig. 3) , suggesting that upon phosphorylation, PKC␣ and ε translocate to the myofilaments during I/R and may target proteins that are relevant to cardiac function.
Phosphorylation of myofilament proteins is increased during I/R in LMW expressing hearts. Given that both PKC␣ and ε translocate to the myofibrils during I/R injury (Fig. 6) , the phosphorylation state of the myofibrillar proteins troponin I and T was analyzed (Fig. 7) , which can affect calcium binding and cross-bridge cycling of the myofibrils (59) . This is total protein phosphorylation, which may be the result of changes in the activity of several kinases/phosphatases. Interestingly, the phosphorylation of both troponins increased significantly in hearts expressing LMW FGF2 after the onset of ischemia through early reperfusion (Fig. 7, A and C) . The initial increase in phosphorylation was seen after 5 min of ischemia, which corresponds to the same time of activation and translocation of PKC␣, suggesting that this kinase may be responsible for these changes. To test this, the phosphorylation of troponin I and T at early ischemia was measured in the absence of PKC␣ and found to be significantly reduced in the HMWKO hearts at the onset of ischemia, back to wild-type levels (Fig. 7, B and D) . Phosphorylation of the troponins was also increased at early reperfusion, the point that corresponds to the time of PKCε activation (Fig. 3) . Interestingly, PKCε inhibition with εV 1-2 did not lower the phosphorylation state of the troponins (data not shown). Therefore, these data indicate that this PKC isoform was not involved in the posttranslational modifications of troponin I or T at early reperfusion, when PKCε is activated and translocated to the myofilament. This does not rule out a role, however, for PKCε in posttranslational modification of other myofibrillar proteins. Actomyosin MgATPase activity is altered in HMWKO hearts during I/R. To determine if LMW FGF2-mediated activation of PKC isoforms during I/R injury affects the cross-bridge cycling activity of the myofibrils, actomyosin MgATPase activity was evaluated (Fig. 8) . The maximum activity of actomyosin MgATPase was elevated in HMWKO hearts during reperfusion (Fig. 8) , which was not abrogated by the absence of PKC␣ or inhibition of PKCε (Fig. 8 and Fig. 9, respectively) . Alternately, the EC 50 was raised in HMWKO hearts compared with wild type at baseline, early ischemia, and early reperfusion, suggesting that calcium activates the myofibril with lowered potency; these changes in myofilament calcium sensitivity in HMWKO hearts were ablated in the absence of PKC␣ at baseline and early ischemia, indicating that this decreased potency is dependent on PKC␣ (Fig. 8) . However, inhibition of PKCε did not have an effect (Fig. 9) . Overall, this suggests that in hearts only expressing LMW FGF2, the presence of PKC␣ results in a decrease in myofilament calcium sensitivity.
DISCUSSION
Our laboratory has previously demonstrated opposing roles for HMW and LMW FGF2 in the functional recovery of the heart after I/R (40, 41) . This study is the first to show that LMW FGF2 requires the activity of two isoforms of PKC, PKCε and PKC␣, which are differentially activated during I/R through distinct parallel pathways. Additionally, the expression of only LMW FGF2 alters the activity of the actomyosin MgATPase in ischemic hearts, corresponding to differences in the phosphorylation of troponin I and T. These results describe a novel mechanism of FGF2-mediated protection from I/R injury through activation of protective PKC isoforms, which then phosphorylate myofibril proteins to modulate postischemic cardiac function (Fig. 10) .
As we have previously described using gain-of-function and loss-of-function models, expression of only LMW FGF2 improves postischemic cardiac function compared with wild-type and Fgf2 KO hearts. These protective effects are dependent on the activity of the FGFR1 (40) , which can activate PKCs via phospholipase C (45, 47) or other scaffolding proteins such as FRS2/Grb (35), which also have the potential to interact with PKCs (42). Here, evidence sug- gests that expression of only LMW FGF2 results in the differential activation of PKC␣ and ε to protect the heart from postischemic dysfunction. While our model identified PKC as necessary for FGF2-induced cardioprotection, early studies examining the role of PKC in protection against I/R injury, particularly ischemic preconditioning, produced conflicting findings (for review, see Ref. 56) . This phenomenon has, in part, been attributed to the different and sometimes opposing roles of multiple isoforms of PKC that have been uncovered in recent years (for review, see Refs. 10, 57). For example, while inhibition of all isoforms of PKC with staurosporine fails to prevent ischemic preconditioning in porcine (65) , activation of simply the ε-isoform of PKC protects the porcine heart from arrhythmia and infarct development (28) . It was later determined that the activation of various isoforms of PKC may result in diverse and opposing effects during I/R, with PKC␦ acting as an injurious element and PKCε behaving as a protective molecule in infarct development during ischemic preconditioning (29) . For this reason, a thorough and complete characterization of the signaling mechanisms of FGF2 must include a description of the specific PKC isoforms that are activated. Therefore, investigation of the targets of PKC␣ and ε was driven by the observation that, while hearts that only express LMW FGF2 are protected from I/R-induced dysfunction, they are not similarly protected from infarct development and tissue death (40, 41) (and see Tables  2 and 4) .
The data presented indicate that PKC␣ is activated to a higher degree during ischemia, while PKCε is activated after reperfusion in hearts only expressing LMW FGF2 compared with wild-type and Fgf2 KO [data not shown and previously published (27) ] hearts. It should be noted that this differs from a mouse model overexpressing all isoforms of FGF2, where the activity of PKC␣ is reduced during I/R (26), suggesting that this increase in PKC␣ activity is a unique result of only LMW FGF2. Conversely, in both models, PKCε activity is increased at early reperfusion, suggesting that this isozyme may contribute to protection from both postischemic cardiac dysfunction and infarct development (seen when all isoforms of FGF2 are overexpressed). While some PKC isoforms can activate one another (58) and cross talk between PKC␣ and ε has been shown to occur in ischemic preconditioning models of cardioprotection (23), this does not appear to be the case here, as PKC␣ and ε are activated independently of one another (Fig. 5) .
Paradoxically, while it is demonstrated in this study that expression of PKC␣ results in higher contractility after I/R injury in HMWKO hearts, it has been established that PKC␣ expression is associated with lowered contractility in nonischemic hearts (9) . Furthermore, phosphorylation of myofibril targets by PKC␣ is maladaptive for heart failure and remodeling (5). This phenomenon illustrates the importance of the conditions under which PKC isoforms are activated. PKC␣ was activated differentially by LMW FGF2 only after the onset of ischemia, an event that precipitates a unique set of intracellular conditions, characterized by acute loss of ATP, and transient but substantial increases in intracellular acidity, and sodium and calcium concentrations, which leads to a distinct manner of injury associated with calcium overload (25) . It is well characterized that PKC isoforms can play varying roles under different circumstances in the heart; for example, PKC␦ is necessary for cardioprotection from I/R triggered by opioid agonists (21) and adenosine-mediated late preconditioning (36) , while this same isoform is detrimental in conditions of ischemic preconditioning (29) and ethanol-induced protection from ischemia (13) . Similarly, it is during the unique events of I/R injury in the presence of LMW FGF2 that the activation of PKC␣ protects the postischemic heart and results in improved cardiac function. We speculate that the reduced levels of myofilament PKC␣ seen in the HMWKO sham mice represent a compensatory change in which myofilament inhibition by PKC␣ is reduced, allowing for a more efficient contractile state. Paradoxically, the increase in myofilament-associated PKC␣ following an acute ischemic challenge may also represent a compensatory change. Molnar and colleagues (46) found that PKC␣ maintains cardiac myofilament force development under conditions that occur during I/R. By contrast, ShintaniIshida and Yoshida (55) report that post-I/R activation of PKC␣ at the sarcoplasmic reticulum exacerbates I/R damage, arguing for subcellular-specific effects of PKC␣. We propose that the reduction in myofilament-associated PKC␣ allows the myofilament complex to function with less hindrance by PKC␣ but that transient activation of myofilament-associated PKC␣ during I/R provides a cardioprotective advantage, possibly through an energy sparing mechanism (51). This hypothetical model incorporates the importance of both timing and subcellular localization of PKC activation, as has been advanced elsewhere (14, 69) . The time-dependent changes in PKC isoform translocation to the myofilaments are interesting and suggestive of a dynamic system during I/R. Although this represents the first report showing time-dependent changes in myofilament-associated PKC isoforms, earlier work by Yoshida and investigators (70) reported similarly dynamic alterations in membrane-associated PKC isoforms. The significance of these changes is difficult to assess, as it would require inhibiting not only the specific isoforms, but at certain times and within the myofilament compartment, to determine the significance of the specific changes. At the moment, this represents an untenable technical challenge and is beyond the scope of the current paper. The impact of PKCs on cardiac functional recovery after I/R is manifested by changes in myofibrillar proteins. As shown here for the first time, alterations in both actomyosin MgATPase activity, and troponin I and T phosphorylation in hearts only expressing LMW FGF2 are dependent on the presence of PKC␣. Troponin I and T have several PKC phosphorylation sites that regulate the calcium affinity of the thin filaments and contractile force (59) . Phosphorylation of the known PKC sites on troponin T produce a reduction in contractile force and calcium sensitivity (60, 61) , while the PKC-targeted residues in troponin I result in a more complex response. Phosphorylation of S23/24, a PKA and PKC␦ target, increases lusitropy and inotropy, while the PKC targets T144 and S43/45 reduce calcium binding cooperativity and contractile force, respectively (34, 38, 46, 60) . Unfortunately, the specific residues that contribute to increased phosphorylation of TnI remain unknown until the availability of reliable and specific phospho-antibodies.
The molecular basis of myocardial dysfunction has been under investigation for a significant period of time, but a singular, definitive mechanism has yet to be identified. Among the most well-supported theories are the "oxyradical" and "calcium hypotheses" (8, 24) . Although each model has component elements that are unique, both hold cardiac myofilaments as central players in the development of the contractile dysfunction that underlies stunning (24) . MacGowan and group (44) support a key role for myofilament protein phosphorylation in the response to acute myocardial ischemia by demonstrating that alterations in troponin I phosphorylation alter the susceptibility of hearts to ischemic injury. However, a recent study by Avner and colleagues (2) shows that myofilament protein oxidation with ischemia mediates a similar reduction in myofilament calcium sensitivity. In chronic models of heart failure, protein oxidation has been linked to functional impairment (12) , suggesting that a prolonged reduction in myofilament calcium sensitivity is not beneficial. Together, these studies suggest that acute changes in the phosphorylation of myofilaments to temporarily decrease myofilament calcium sensitivity confer a protective effect, but that long-term damage to cardiac myofilaments by oxidation is associated with impaired function.
Phosphorylation of regulatory proteins, including troponin I and T, myosin light chain, and myosin-binding protein C, have been implicated in myofilament calcium sensitivity, which subsequently affects force development (15, 34, 44, 60, 61, 66) . In the studies presented here, increased troponin phosphorylation during I/R mirrors an increase in the EC 50 of actomyosin MgATPase, suggesting that LMW FGF2 activation of PKC␣ results in a lowered potency of calcium-mediated activation of the ATPase. This is particularly important during ischemia, where calcium overload is a primary effector of the cardiac dysfunction seen during late reperfusion; by requiring a higher calcium concentration to achieve the same level of ATPase activity, myofilament activity and ATP consumption are reduced, and the damage caused by calcium overload is slowed. Thus a temporary increase in EC 50 during ischemia results in a mitigation of calcium-induced injury and stunning. This PKC-dependent transient depression of actomyosin MgATPase calcium sensitivity has previously been demonstrated to result in cardioprotection (51) .
The effects of PKC on actomyosin MgATPase activity are complex, dependent on the site of phosphorylation and the conditions of activation. Burkart et al. (11) showed that mutating S43 and S45 in cardiac troponin I to E43 and E45 to mimic PKC phosphorylation decreased maximum actomyosin MgATPase activity. By contrast, a similar mutation at T144 had no effect on maximum myofilament ATP consumption, demonstrating that the PKC-dependent depression of maximum actomyosin MgATPase activity is specific to T144 phosphorylation. More recently, Engel and investigators (19) found that myofilament regulation via PKC-preferred sites is altered under conditions that occur during prolonged ischemia. Thus, while physiological and biochemical investigations of PKCdependent regulation of myofilament function present a sound basis from which to build an understanding of myocardial PKC signaling, understanding the role of this molecular messenger activates PKC␣, which phosphorylates troponin I and T at the myofibril and transiently reduces calcium sensitivity (EC50), to protect the heart during ischemia.
in disease requires that its regulation and impact be investigated in pathological models similar to those used here.
In addition, increased levels of intracellular ATP during ischemia have been seen when recombinant FGF2 is administered to ischemic hearts (30) . Further studies are currently determining whether depressed activity of contractile proteins mediated by PKC␣ during I/R may slow ATP depletion and intracellular calcium overload.
The model used here studied the effects of the LMW isoform of FGF2 by ablating HMW FGF2 expression. It should be noted that studies by Jiang et al. (31) found that the response of the ischemic heart to exogenously added recombinant rat HMW FGF2 protected the heart from ischemic injury and activated PKC␣. This result, while contradictory on the surface, is not surprising in view of the fact that exogenous HMW FGF2 shares the LMW FGF2 FGFR1 binding domain and is expected to act similarly on the extracellular domain of the FGFR1 receptor, when introduced as an external source (50) . We have determined previously that LMW FGF2, and not HMW FGF2, is released outside of the cell and that this is the case both under normal circumstances and during I/R injury (26) . Our investigations seek to determine the activities of endogenous HMW and LMW FGF2 on I/R in a physiological setting, and it is clear that HMW FGF2 expressed by the cardiomyocyte, as demonstrated here and previously by our laboratory (39) , plays a different role than HMW FGF2 applied exogenously, specifically, producing a decrease in cardiac function.
An important caveat for the interpretation of these studies is that the use of global knockouts does not preclude the possibility for noncardiomyocyte effects on postischemic function. We have minimized potential systemic influence by conducting the entire ischemia and reperfusion event in an ex vivo working heart system. However, the use of the intact heart indicates that there may be potential roles for fibroblasts, vascular tissue, and nerve tissue in influencing the outcome of the I/R injury via a paracrine effect. These other cell types, while making up the minority of tissue present in the heart, are still present (4) and cannot be ruled out as possible sources contributing to the effects described in this study.
While these studies elucidate a key component of the LMW FGF2-induced cardioprotection signal transduction pathway, ongoing work is addressing some remaining questions, in particular the effect of calcium handling proteins in LMW FGF2-mediated protection. As Braz and colleagues (9) have elegantly shown, PKC␣ can modulate cardiac contractility by altering the affinity of phospholamban for the sarco(endo)plasmic reticulum Ca 2ϩ -ATPase, through phosphorylation of protein phosphatase 1 inhibitor-1. Examination of the LMW FGF2-induced effects of PKC␣ during I/R on sarcoplasmic reticulum protein activity may shed further light into the differences in postischemic function observed between the wild-type and HMWKO groups.
The findings presented here are the first to demonstrate that LMW FGF2-induced cardioprotection against postischemic cardiac dysfunction depends on the activation of both PKC␣ and PKCε. Moreover, the activation of PKC␣ is associated with the phosphorylation and regulation of proteins at the myofibril, leading to the modulation of the activity of actomyosin ATPase during ischemia. This understanding will better enable the development of LMW FGF2 as a therapeutic target for ischemic heart disease.
